Predicted protein targets (top 11)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | FABP3 | P05413 | 2/20 | 0.40 |
| ▸ | FABP4 | P15090 | 2/20 | 0.40 |
| ▸ | FABP5 | Q01469 | 1/20 | 0.40 |
| ▸ | GAA | P10253 | 1/20 | 0.34 |
| ▸ | SOAT2 | O75908 | 1/20 | 0.31 |
| ▸ | MYC | P01106 | 1/20 | 0.31 |
| ▸ | SOAT1 | P35610 | 1/20 | 0.31 |
| ▸ | MAP2K3 | P46734 | 1/20 | 0.31 |
| ▸ | ENPP3 | O14638 | 1/20 | 0.30 |
| ▸ | ENPP1 | P22413 | 1/20 | 0.30 |
| ▸ | HDAC1 | Q13547 | 1/20 | 0.30 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL5471203 | 0.88 | NLRP3 (0.34) | — | |
| SCHEMBL6938810 | 0.83 | FABP3 (0.37) | FABP3FABP4FABP5GAASOAT2 | |
| SCHEMBL8706010 | 0.81 | FABP3 (0.38) | FABP3FABP4FABP5GAASOAT2 | |
| SCHEMBL7104863 | 0.79 | FABP3 (0.40) | FABP3FABP4FABP5GAA | |
| SCHEMBL7108814 | 0.77 | FABP3 (0.41) | FABP3FABP4FABP5GAA | |
| SCHEMBL7207646 | 0.72 | ALDH1A1 (0.38) | FABP3FABP4FABP5 | |
| SCHEMBL7105200 | 0.67 | FABP3 (0.39) | FABP3FABP4FABP5GAAHDAC1 | |
| SCHEMBL7206928 | 0.66 | FABP3 (0.41) | FABP3FABP4FABP5GAASOAT2 | |
| SCHEMBL6940243 | 0.66 | FABP3 (0.39) | FABP3FABP4FABP5GAASOAT2 | |
| SCHEMBL7109323 | 0.64 | FABP3 (0.39) | FABP3FABP4FABP5GAASOAT2 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 25 patents — showing the first 20. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-20070155832-A1 | Use of sulfonamide compounds for the treatment of diabetes and/or obesity | ASTRAZENECA AB (SE) | 2007-07-05 | — | — | US | claimed |
| EP-0841913-B1 | USE OF SULFAMIC ACID DERIVATIVES, ACYL SULFONAMIDES OR SULFONYL CARBAMATES FOR THE MANUFACTURE OF A MEDICAMENT FOR LOWERING LIPOPROTEIN LEVELS | WARNER LAMBERT CO (US) | 2003-02-05 | — | — | EP | claimed |
| US-20020183384-A1 | Methods of treating nuclear factor-kappa B mediated diseases and disorders | CORNICELLI JOSEPH ANTHONY (US) | 2002-12-05 | — | — | US | claimed |
| EP-1236468-A1 | Sulfonylaminocarbonyl derivatives for the treatment of nuclear factor-kappa B mediated diseases and disorders | WARNER-LAMBERT COMPANY (US) | 2002-09-04 | — | — | EP | claimed |
| US-6117909-A | TREATING CARDIOVASCULAR DISEASE SUCH AS STROKE, PERIPHERAL VASCULAR DISEASES, AND RESTENOSIS. | WARNER-LAMBERT COMPANY (US) | 2000-09-12 | — | — | US | claimed |
| EP-0698010-B1 | N-ACYL SULFAMIC ACID ESTERS (OR THIOESTERS), N-ACYL SULFONAMIDES, AND N-SULFONYL CARBAMIC ACID ESTERS (OR THIOESTERS) AS HYPERCHOLESTEROLEMIC AGENTS | WARNER LAMBERT CO (US) | 1999-04-14 | — | — | EP | claimed |
| EP-0841913-A1 | USE OF SULFAMIC ACID DERIVATIVES, ACYL SULFONAMIDES OR SULFONYL CARBAMATES FOR THE MANUFACTURE OF A MEDICAMENT FOR LOWERING LIPOPROTEIN LEVELS | WARNER-LAMBERT COMPANY (US) | 1998-05-20 | — | — | EP | claimed |
| WO-1997005868-A1 | USE OF SULFAMIC ACID DERIVATIVES, ACYL SULFONAMIDES OR SULFONYL CARBAMATES FOR THE MANUFACTURE OF A MEDICAMENT FOR LOWERING LIPOPROTEIN LEVELS | WARNER-LAMBERT COMPANY (US) | 1997-02-20 | — | — | WO | claimed |
| EP-0698010-A1 | N-ACYL SULFAMIC ACID ESTERS (OR THIOESTERS), N-ACYL SULFONAMIDES, AND N-SULFONYL CARBAMIC ACID ESTERS (OR THIOESTERS) AS HYPERCHOLESTEROLEMIC AGENTS | WARNER-LAMBERT COMPANY (US) | 1996-02-28 | — | — | EP | claimed |
| US-5491172-A | ACYLCOENZYME A:CHOLESTEROL ACYLTRANSFERASE INHIBITORS | WARNER-LAMBERT COMPANY (US) | 1996-02-13 | — | — | US | claimed |
| WO-1994026702-A1 | N-ACYL SULFAMIC ACID ESTERS (OR THIOESTERS), N-ACYL SULFONAMIDES, AND N-SULFONYL CARBAMIC ACID ESTERS (OR THIOESTERS) AS HYPERCHOLESTEROLEMIC AGENTS | WARNER-LAMBERT COMPANY (US) | 1994-11-24 | — | — | WO | claimed |
| US-20070155832-A1 | Use of sulfonamide compounds for the treatment of diabetes and/or obesity | ASTRAZENECA AB (SE) | 2007-07-05 | — | — | US | disclosed |
| EP-1682112-A1 | USE OF SULFONAMIDE COMPOUNDS FOR THE TREATMENT OF DIABETES AND/OR OBESITY | AstraZeneca AB (SE) | 2006-07-26 | — | — | EP | disclosed |
| WO-2005044250-A1 | USE OF SULFONAMIDE COMPOUNDS FOR THE TREATMENT OF DIABETES AND/OR OBESITY | ASTRAZENECA AB (SE) | 2005-05-19 | — | — | WO | disclosed |
| EP-0841913-B1 | USE OF SULFAMIC ACID DERIVATIVES, ACYL SULFONAMIDES OR SULFONYL CARBAMATES FOR THE MANUFACTURE OF A MEDICAMENT FOR LOWERING LIPOPROTEIN LEVELS | WARNER LAMBERT CO (US) | 2003-02-05 | — | — | EP | disclosed |
| US-5633287-A | N-acyl sulfamic acid esters (or thioesters), N-acyl sulfonamides, and n-sulfonyl carbamic acid esters (or thioesters) as hypercholesterolemic agents | WARNER-LAMBERT COMPANY (US) | 1997-05-27 | — | — | US | disclosed |
| WO-1997005868-A1 | USE OF SULFAMIC ACID DERIVATIVES, ACYL SULFONAMIDES OR SULFONYL CARBAMATES FOR THE MANUFACTURE OF A MEDICAMENT FOR LOWERING LIPOPROTEIN LEVELS | WARNER-LAMBERT COMPANY (US) | 1997-02-20 | — | — | WO | disclosed |
| EP-0698010-A1 | N-ACYL SULFAMIC ACID ESTERS (OR THIOESTERS), N-ACYL SULFONAMIDES, AND N-SULFONYL CARBAMIC ACID ESTERS (OR THIOESTERS) AS HYPERCHOLESTEROLEMIC AGENTS | WARNER-LAMBERT COMPANY (US) | 1996-02-28 | — | — | EP | disclosed |
| US-5491172-A | ACYLCOENZYME A:CHOLESTEROL ACYLTRANSFERASE INHIBITORS | WARNER-LAMBERT COMPANY (US) | 1996-02-13 | — | — | US | disclosed |
| WO-1994026702-A1 | N-ACYL SULFAMIC ACID ESTERS (OR THIOESTERS), N-ACYL SULFONAMIDES, AND N-SULFONYL CARBAMIC ACID ESTERS (OR THIOESTERS) AS HYPERCHOLESTEROLEMIC AGENTS | WARNER-LAMBERT COMPANY (US) | 1994-11-24 | — | — | WO | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (2 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20020183384-A1 | Methods of treating nuclear factor-kappa B mediated diseases and disorders | NFKBIA, IKBKB, RELA | FABP3 40/4885FABP4 192/4885FABP5 229/4885 |
| US-20070155832-A1 | Use of sulfonamide compounds for the treatment of diabetes and/or obesity | GPR119, DGAT1, DGAT2 | FABP3 1015/4885FABP4 226/4885FABP5 1990/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.